VivoSim Labs (VIVS) Non Operating Investment Income (2022 - 2023)
VivoSim Labs (VIVS) posted Non Operating Investment Income of $12000.0 for Q2 2023, down 92.11% on a QoQ basis from $152000.0 in Q1 2023, and up 340.0% year-over-year from $2727.3 in Q2 2022.
Powered by 
Analysis
VivoSim Labs (VIVS) Non Operating Investment Income (2022 - 2023) Analysis & Trends
VivoSim Labs has reported Non Operating Investment Income for 2 years, with the latest figure at $12000.0 in Q2 2023.
- On a quarterly basis, Non Operating Investment Income rose 340.0% year-over-year to $12000.0 in Q2 2023; TTM through Mar 2024 was $12000.0, a 58.62% decrease from a year earlier, with the FY2026 full-year figure at $94000.0, changed N/A from the prior year.
- Non Operating Investment Income was $12000.0 for Q2 2023 at VivoSim Labs, down from $152000.0 in the prior quarter.
- The five-year high for Non Operating Investment Income was $152000.0 in Q1 2023, with the low at -$70000.0 in Q3 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Iqvia Holdings | 44.72 Bn | 42.64 Bn | 1.44 Bn | - |
| 2 | Medpace Holdings | 17.37 Bn | 16.87 Bn | 201.64 Mn | - |
| 3 | Icon | 13.65 Bn | 12.72 Bn | 479.29 Mn | -32.95 Mn |
| 4 | Charles River Laboratories International | 13.13 Bn | 12.94 Bn | 452.07 Mn | - |
| 5 | Fortrea Holdings | 1.89 Bn | 1.72 Bn | 139.20 Mn | - |
| 6 | Evotec SE | 574.75 Mn | 148.87 Mn | - | - |
| 7 | Ginkgo Bioworks Holdings | 439.63 Mn | 355.09 Mn | 18.44 Mn | 1.99 Mn |
| 8 | Champions Oncology | 69.43 Mn | 65.03 Mn | 7.70 Mn | - |
| 9 | MindWalk Holdings | 51.76 Mn | 46.29 Mn | 1.61 Mn | - |
| 10 | VivoSim Labs | 1.37 Mn | 1.37 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2023 | 12,000.00 |
| Mar 31, 2023 | 152,000.00 |
| Dec 31, 2022 | -48,000.00 |
| Sep 30, 2022 | -70,000.00 |
| Jun 30, 2022 | -5,000.00 |